Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ann D, Bass"'
Autor:
Rehana Z Hussain, Peter V Sguigna, Annette Okai, Crystal Wright, Mariam Madinawala, Ann D Bass, Gary R Cutter, Navid Manouchehri, Olaf Stuve
Publikováno v:
Journal of Central Nervous System Disease, Vol 14 (2022)
Background Natalizumab is a recombinant humanized monoclonal antibody (mAb) against α4-integrin that is approved for relapsing forms of multiple sclerosis (MS). Natalizumab is associated with an increased risk of developing progressive multifocal le
Externí odkaz:
https://doaj.org/article/c1bc506e593a48c1b9ba6718196b30c8
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Autor:
Alasdair J. Coles, Douglas L. Arnold, Ann D. Bass, Aaron L. Boster, D. Alastair S. Compston, Óscar Fernández, Eva Kubala Havrdová, Kunio Nakamura, Anthony Traboulsee, Tjalf Ziemssen, Alan Jacobs, David H. Margolin, Xiaobi Huang, Nadia Daizadeh, Madalina C. Chirieac, Krzysztof W. Selmaj
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Background: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 consecutive days 12 months later significantly improved outcomes versus subcutaneous interferon beta-1a (SC IFNB-1
Externí odkaz:
https://doaj.org/article/0fa2ae77784345bda11b4afff0c00fe1
Autor:
Krista Barclay, Robert Carruthers, Anthony Traboulsee, Ann D. Bass, Christopher LaGanke, Antonio Bertolotto, Aaron Boster, Elisabeth G. Celius, Jérôme de Seze, Dionisio Dela Cruz, Mario Habek, Jong-Mi Lee, Volker Limmroth, Sven G. Meuth, Celia Oreja-Guevara, Patricia Pagnotta, Cindy Vos, Tjalf Ziemssen, Darren P. Baker, Bart Van Wijmeersch
Publikováno v:
Frontiers in Neurology, Vol 10 (2019)
Multiple sclerosis (MS) is a chronic autoimmune neurological disease that typically affects young adults, causing irreversible physical disability and cognitive impairment. Alemtuzumab, administered intravenously as 2 initial courses of 12 mg/day (5
Externí odkaz:
https://doaj.org/article/5a2d464a5167440db92790a49c321afc
Autor:
Ann D Bass, Joshua Katz, Edward Fox, Derrick Robertson, Danielle E. Harlow, Jacob A. Sloane, Brooke Hayward, Augusto Miravalle, Lori A Lebson
Publikováno v:
Neurodegenerative Disease Management. 11:99-111
Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are approved for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS and active secondary progressive MS. However, real-world data on cladribi
Autor:
Ann D Bass, Deidre Kile, Scott D. Newsome, Gabriel Pardo, B Musch, Robert A. Bermel, Pavle Repovic, Ashish Pradhan, J. W. Lindsey, Aram Zabeti, Emmanuelle Waubant
Publikováno v:
Annals of Clinical and Translational Neurology
Annals of Clinical and Translational Neurology, Vol 8, Iss 3, Pp 711-715 (2021)
Annals of Clinical and Translational Neurology, Vol 8, Iss 3, Pp 711-715 (2021)
The CHORDS trial evaluated ocrelizumab (OCR) in patients with relapsing‐remitting multiple sclerosis who had a suboptimal response to previous disease‐modifying treatment. The objective of the present study was to assess the safety of shorter OCR
Autor:
Colin P. Mitchell, Kersten Sharrock, Lori Mayer, Ann D Bass, Barry A Singer, Matt Mandel, Bart Van Wijmeersch, Aaron Boster, Mathias Mäurer
Publikováno v:
International Journal of MS Care. 22:158-164
Background: The vsMS survey was conducted to better understand the negative effects of fatigue, cognitive impairment, emotional burden, and decreased physical functioning on the personal, professional, and social lives of individuals with multiple sc
Autor:
Adam Cuker, Christopher LaGanke, Congor Nadj, Alexandre Guerreiro, Sven G. Meuth, Brian Steingo, Bart Van Wijmeersch, Karthinathan Thangavelu, Mark A Agius, Krzysztof Selmaj, Timothy Thoits, Claudio E Rodriguez, David Margolin, Ann Jannsens, Tjalf Ziemssen, Darren P Baker, Ann D Bass
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Background: Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk. Objective: To examine ITP incidence, treatment, and outcomes during the clinical
Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial
Autor:
Eva Havrdova, Krzysztof Selmaj, Douglas L. Arnold, Kunio Nakamura, Tjalf Ziemssen, Aaron Boster, D Alastair S Compston, Alasdair Coles, Xiaobi Huang, Alan Jacobs, Madalina C Chirieac, Ann D Bass, David Margolin, Anthony Traboulsee, Oscar Fernandez, Nadia Daizadeh
Publikováno v:
Therapeutic Advances in Neurological Disorders
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Therapeutic Advances in Neurological Disorders, Vol 14 (2021)
Funder: Bayer HealthCare Pharmaceuticals
Funder: Sanofi; FundRef: https://doi.org/10.13039/100004339
Background:: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 co
Funder: Sanofi; FundRef: https://doi.org/10.13039/100004339
Background:: In the 2-year CARE-MS I and II trials, alemtuzumab 12 mg administered on 5 consecutive days at core study baseline and on 3 co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f075dbb5bd06daf0d1818bd7271b139
https://www.repository.cam.ac.uk/handle/1810/324468
https://www.repository.cam.ac.uk/handle/1810/324468
Autor:
Darren P Baker, Carlos Navas, Carolina Ionete, Mar Tintoré, Zia Choudhry, Rafael Arroyo, David Rog, Nadia Daizadeh, Aaron Boster, Bernard M. J. Uitdehaag, Sara Eichau, Lívia Sousa, Topaz investigators, Jennifer Ravenscroft, Volker Limmroth, Carlo Pozzilli, Alexey Boyko, Ann D Bass, Care-Ms I, Care-Ms Ii, Camms, Daniel Pelletier
Publikováno v:
Multiple Sclerosis and Related Disorders, 49:102717. Elsevier
Scientia
Bass, A D, Arroyo, R, Boster, A L, Boyko, A N, Eichau, S, Ionete, C, Limmroth, V, Navas, C, Pelletier, D, Pozzilli, C, Ravenscroft, J, Sousa, L, Tintoré, M, Uitdehaag, B M J, Baker, D P, Daizadeh, N, Choudhry, Z, Rog, D & CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators 2021, ' Alemtuzumab outcomes by age : Post hoc analysis from the randomized CARE-MS studies over 8 years ', Multiple Sclerosis and Related Disorders, vol. 49, 102717 . https://doi.org/10.1016/j.msard.2020.102717
Scientia
Bass, A D, Arroyo, R, Boster, A L, Boyko, A N, Eichau, S, Ionete, C, Limmroth, V, Navas, C, Pelletier, D, Pozzilli, C, Ravenscroft, J, Sousa, L, Tintoré, M, Uitdehaag, B M J, Baker, D P, Daizadeh, N, Choudhry, Z, Rog, D & CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators 2021, ' Alemtuzumab outcomes by age : Post hoc analysis from the randomized CARE-MS studies over 8 years ', Multiple Sclerosis and Related Disorders, vol. 49, 102717 . https://doi.org/10.1016/j.msard.2020.102717
Alemtuzumab; Efficacy; Safety Alemtuzumab; Eficacia; Seguridad Alemtuzumab; Eficàcia; Seguretat Background Alemtuzumab significantly improved clinical and MRI outcomes vs. subcutaneous interferon beta-1a (SC IFNB-1a) in the CARE-MS trials (NCT005303
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83728c1f13a64a694c1b1f493edb2e15
https://hdl.handle.net/10668/17008
https://hdl.handle.net/10668/17008
Autor:
Ann D, Bass, Bart, Van Wijmeersch, Lori, Mayer, Mathias, Mäurer, Aaron, Boster, Matt, Mandel, Colin, Mitchell, Kersten, Sharrock, Barry, Singer
Publikováno v:
Int J MS Care
BACKGROUND: The vsMS survey was conducted to better understand the negative effects of fatigue, cognitive impairment, emotional burden, and decreased physical functioning on the personal, professional, and social lives of individuals with multiple sc